(Q34458735)

2 August 2017

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial (English)

1 reference

2 August 2017

phase II clinical trial

0 references

1 reference

1 reference

tuberculous meningitis

1 reference

1 reference

9

Reinout van Crevel

0 references

Sofiati Dian

object named as

Sofiati Dian

3

0 references

Lika Apriani

object named as

Lika Apriani

4

1 reference

ORCID Public Data File 2021

André van der Ven

6

object named as

Andre J van der Ven

1 reference

2 August 2017

1

Rovina Ruslami

1 reference

2 August 2017

A Rizal Ganiem

2

1 reference

2 August 2017

Tri Hanggono Achmad

5

1 reference

2 August 2017

George Borm

7

1 reference

2 August 2017

Rob E Aarnoutse

8

1 reference

2 August 2017

25 October 2012

1 reference

Lancet Infectious Diseases

2 August 2017

1 reference

2 August 2017

13

1 reference

2 August 2017

1

1 reference

2 August 2017

27-35

1 reference

The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Cerebrospinal fluid concentrations of antituberculosis agents in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Tuberculous meningitis: a uniform case definition for use in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Therapeutic drug monitoring in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970264-5

7 January 2021

10.1016/S1473-3099(12)70264-5

Identifiers

DOI

1 reference

2 August 2017

1 reference